Ustekinumab is a fully human IgG1k monoclonal antibody that notably targets the common p40 subunit of IL-12 and IL-23, well-defined key mediators of psoriasis that are able to stimulate two emerging Th-cell subsets of CD4 + T, Th17 and Th22 cells with a crucial role in immune response to tissue inflammation. The gene discussed is CD4; the disease is psoriasis.